A phase 1 study of dendrimer-docetaxel (DEP(TM) Docetaxel) in patients with advanced cancer.
Phase 1
Completed
- Conditions
- CancerCancer - Any cancer
- Registration Number
- ACTRN12614000171617
- Lead Sponsor
- Starpharma Pty Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Patients with histologically or cytologically confirmed advanced or metastatic cancer for which no standard or curative therapy exists; life expectancy of greater than 12 weeks;measurable or evaluable disease by RECIST.
Exclusion Criteria
Allergy to docetaxel or other components of study therapy or compounds of similar chemical composition; uncontrolled intercurrent illness; participation in a study of an investigational agent within 30 days prior to first study therapy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Dendrimer-docetaxel conjugate DTX-SPL8783 mechanism action enhanced permeability retention effect solid tumors
Comparative pharmacokinetics efficacy DEP Docetaxel versus standard docetaxel advanced solid tumors
Predictive biomarkers dendrimer nanoparticle drug delivery docetaxel efficacy solid tumor patients
Safety tolerability profile dendrimer-docetaxel DTX-SPL8783 versus conventional docetaxel phase 1
Starpharma DEP dendrimer platform drug delivery oncology conjugates clinical development pipeline